VisionCare Ophthalmic Technologies Announces Presentations at the Annual Meeting of the American Society of Cataract and Refractive Surgery

Visual Prosthetic Device for Macular Degeneration Highlighted in

Scientific Sessions

Mar 17, 2006, 00:00 ET from VisionCare Ophthalmic Technologies, Inc.

    SARATOGA, Calif., March 17 /PRNewswire/ -- VisionCare Ophthalmic
 Technologies, Inc., a developer of advanced visual prosthetic devices for the
 treatment of age-related macular degeneration (AMD), announced today three
 presentations on its platform technology are scheduled at the upcoming annual
 symposium of the American Society of Cataract and Refractive Surgery (ASCRS)
 March 18 - 21, 2006, in San Francisco. Podium presentations are scheduled at
 the Moscone Convention Center as follows:
     Clinical Trial Presentations
      --  Saturday, March 18, 1:07 PM, Moscone Room 301
          Implantable Miniature Telescope in Patients with ARMD: Final
          Assessment of Surgical Technique from the Phase II/III Trial
          Mark Packer, MD
      --  Monday, March 20, 1:32 PM, Moscone Room 110
          Implantable Miniature Telescope in Patients with Macular
          Degeneration: 1-Year Results
          R. Doyle Stulting, MD, PhD
     Preclinical Study Presentation
     --  Saturday, March 18, 1:02 PM, Moscone Room 301
         Preclinical Studies of Implantable Miniature Telescope for
         Pseudophakic Eyes
         Ehud I. Assia, MD
     At ASCRS, VisionCare is located in Booth #3139 at the Moscone Convention
 Center in San Francisco.
     About the Visual Prosthetic Device
     The investigational Implantable Miniature Telescope (IMT(TM) by Dr. Isaac
 Lipshitz) is designed to be a permanent solution for moderate to profound
 vision loss due to advanced, end-stage forms of AMD that have no current
 surgical or medical treatment options. Smaller than a pea, the telescope
 prosthetic device is implanted in one eye in an outpatient surgical procedure.
 In the implanted eye, the device renders enlarged central vision images over a
 wide area of the retina to improve central vision, while the non-operated eye
 provides peripheral vision for mobility and orientation.
     The prospective IMT002 Phase II/III trial, evaluating the safety and
 efficacy of VisionCare's investigational device in individuals with moderate
 to profound bilateral central vision impairment associated with end-stage AMD,
 is complete. The trial enrolled over 200 patients at 28 leading medical
 universities and ophthalmic centers across the country. VisionCare has
 submitted a Premarket Approval (PMA) Application which seeks regulatory
 approval for the telescope prosthetic device to treat central vision loss due
 to advanced, irreversible forms of AMD. The Food and Drug Administration (FDA)
 has assigned the application expedited review status.
     About Macular Degeneration
     Macular degeneration is a disorder of the central retina, or macula, which
 is responsible for detailed vision that controls important functional visual
 activities like reading, recognizing faces, and watching television. According
 to the National Eye Institute over 1.7 million Americans over age 50 suffer
 mild to profound vision loss from advanced AMD, which culminates as end-stage
 AMD. Approximately half of the individuals living with advanced AMD are
 affected in both eyes.
     About VisionCare
     VisionCare Ophthalmic Technologies, Inc., headquartered in Saratoga, CA is
 a privately-held company focused on development, manufacturing, and marketing
 of visual prosthetic devices. The Implantable Miniature Telescope was invented
 by company founders, Isaac Lipshitz, M.D. and Yossi Gross. Information on
 VisionCare can be found at

SOURCE VisionCare Ophthalmic Technologies, Inc.